title: Clinical evidence for immunomodulatory effects of probiotic bacteria.
abstract: Close, tightly orchestrated interactions between the intestinal epithelium and the mucosa-associated immune system are critical for normal intestinal absorptive and immunological functions. Recent data indicate that commensal intestinal microbiota represents a major modulator of intestinal homeostasis. This review analyzes the process of intestinal colonization and the interaction of microbiota with the intestinal epithelium and mucosal immune system, with special reference to the first years of extrauterine life. Dysregulation of the symbiotic interaction between intestinal microbiota and the mucosa may result in a pathological condition with potential clinical repercussions. Based on the concept that there is a beneficial and symbiotic relation between the host and endogenous microbiota, strategies aimed at directly modulating intestinal microbiota with regard to disease prevention or treatment have been developed. One strategy involves administering viable probiotic bacteria. Clinical evidence for the beneficial effect of probiotics in the prevention and/or treatment of necrotizing enterocolitis, infectious and antibiotic-associated diarrhea, allergic diseases, and inflammatory bowel disorders is reviewed herein.
authors.affiliation: Department of Pediatrics, Hôpital Necker-Enfants Malades, Paris, France. frank.ruemmele@nck.aphp.fr
authors.forename: F M
authors.initials: FM
authors.lastname: Ruemmele
authors.forename: D
authors.initials: D
authors.lastname: Bier
authors.forename: P
authors.initials: P
authors.lastname: Marteau
authors.forename: G
authors.initials: G
authors.lastname: Rechkemmer
authors.forename: R
authors.initials: R
authors.lastname: Bourdet-Sicard
authors.forename: W A
authors.initials: WA
authors.lastname: Walker
authors.forename: O
authors.initials: O
authors.lastname: Goulet
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D003967:Diarrhea / Q000139:chemically induced / Q000382:microbiology / Q000517:prevention & control*; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D018928:Immunity, Mucosal; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D007413:Intestinal Mucosa / Q000276:immunology* / Q000382:microbiology*; D019936:Probiotics
chemical_list: D000900:Anti-Bacterial Agents